ライフサイエンスコーパス: palifermin

1 tis in the placebo group received open-label palifermin.

2 quent cycles (a total of 17) with open-label palifermin.

3 ts received placebo and 28 patients received palifermin.

4 patients reported less severe symptoms with palifermin.

5 Palifermin (180 microg per kg of body weight) or placebo

6 Palifermin (180-720 mug/kg) was given on day -7 before H

7 Six patients (placebo = 2, palifermin = 4) experienced a total of 11 dose-limiting

8 ndomly assigned to receive either placebo or palifermin (40 microg/kg for 3 consecutive days) before

9 Patients were randomly assigned 2:1 to palifermin 60 microg/kg or placebo once weekly for 10 do

10 ors to receive either recombinant human KGF (palifermin 60 mug/kg) or placebo (0.9% sodium chloride s

11 h hematologic cancers; 106 patients received palifermin (60 microg per kilogram of body weight per da

12 verse events were similar between arms (98%, palifermin; 93%, placebo).

13 Palifermin (a recombinant human keratinocyte growth fact

14 Palifermin, a recombinant human keratinocyte growth fact

15 Palifermin, a recombinant N-truncated keratinocyte growt

16 Palifermin administered at the indicated dosing regimen

17 Sixty-seven patients received palifermin and 32 received placebo.

18 rty-nine reports met the inclusion criteria: palifermin and dexrazoxane, three reports (two studies)

19 or= 2 mucositis was 6.5 and 8.1 weeks in the palifermin and placebo groups, respectively (P = .157).

20 Palifermin appeared to reduce mucositis, dysphagia, and

21 In the palifermin arm, median time to severe OM was delayed (47

22 Ten once-weekly doses of palifermin at 60 microg/kg were well tolerated.

23 A single dose of palifermin before each cycle reduced the incidence and s

24 Palifermin can be considered as the prototype mitigant.

25 higher OM was lower in patients who received palifermin compared with placebo (29% v 61% in cycle 1;

26 Palifermin did not alter tumor response or survival.

27 Most patients completed treatment, but palifermin did not reduce the morbidity of concurrent ch

28 Palifermin doses were 40 mug/kg per day (cohort 1 only)

29 Future studies should evaluate higher palifermin doses with longer and more standardized asses

30 ucted a phase 1/2 trial evaluating high-dose palifermin for preventing severe chronic GVHD (CGVHD) in

31 quent in the placebo group (31%) than in the palifermin group (14%).

32 cycles (range, 1 to 6) were completed by the palifermin group and 2 (range, 1 to 6) by the placebo gr

33 de 3 or 4 was 3 days (range, 0 to 22) in the palifermin group and 9 days (range, 0 to 27) in the plac

34 mucositis was 6 days (range, 1 to 22) in the palifermin group and 9 days (range, 1 to 27) in the plac

35 ion (WHO) grade 3 or 4 was 63 percent in the palifermin group and 98 percent in the placebo group (P<

36 s were thickening of oral mucosa (72% in the palifermin group vs. 31% in the placebo group; P = 0.007

37 grade >/= 2 was lower (67% v 80%), favoring palifermin; however, the differences were not significan

38 is study assessed the efficacy and safety of palifermin in patients receiving concurrent chemoradioth

39 who had severe mucositis received open-label palifermin in subsequent cycles.

40 hese results support the clinical benefit of palifermin in the HSCT setting, providing evidence that

41 Palifermin is recommended to decrease severe mucositis i

42 sttransplant lymphocyte phenotyping suggests palifermin modulates regulatory and naive CD4+ T-cell nu

43 tudy assessed the safety and tolerability of palifermin (n = 69) as compared with placebo (n = 31) in

44 The palifermin (n = 94) and placebo (n = 94) arms were well

45 randomly assigned in a 2:1 ratio to receive palifermin or placebo.

46 We tested the ability of palifermin (recombinant human keratinocyte growth factor

47 Although palifermin reduced severe functional OM, its role in the

48 Compared with placebo, palifermin reduced the cumulative incidence of moderate

49 Palifermin reduced the duration and severity of oral muc

50 Palifermin reduced the incidence and duration of severe

51 Palifermin reduces mucositis when given in multiple dose

52 Patients receiving palifermin reported statistically significant improvemen

53 nce of severe OM was significantly lower for palifermin than for placebo (54% v 69%; P = .041).

54 d study evaluated the efficacy and safety of palifermin to reduce OM associated with definitive chemo

55 investigation is needed to determine whether palifermin use will facilitate greater adherence to chem

56 Palifermin was associated with reduced incidence and mea

57 As compared with placebo, palifermin was associated with significant reductions in

58 We conclude that palifermin was generally safe in allogeneic HSCTs but ha

59 Overall, palifermin was safe and well tolerated.

60 Palifermin was well tolerated, with self-limiting rash a

61 s GVHD in preclinical models, lower doses of palifermin were ineffective in humans.

62 These findings indicate that high-dose palifermin with RIC is safe and may prevent AGVHD, altho

63 is double-blind study compared the effect of palifermin with that of a placebo on the development of